NFE2L2 and pulmonary arterial hypertension: Co-exposure to EGFR and MEK inhibitors attenuated the B[a]P-triggered accumulation of NRF2 (Fig. 4a), suggesting that NRF2 may be involved in the PAH-specific upregulation of AKR1C3.